While the cardioprotective effects of SGLT2 inhibitors—including reductions in cardiovascular death, myocardial infarction, and stroke in high-risk patients (28–30), as well as benefits on left ventricular remodeling and neurohormonal activation—are well-documented (31, 32), our data point to a novel application: protecting the retinal microvasculature from the specific insult of CHD. The gene discussed is SLC5A2; the disease is stroke disorder.